ImmuCell announced the appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board of Directors, effective as of today, as the company strengthens its innovation strategy and corporate governance structure.
Alongside the appointments, ImmuCell revealed plans to transition to a seven-person board composed of six independent directors and the CEO, and to establish a new Strategy and Technology Committee. The move is designed to enhance strategic oversight and accelerate innovation across the company’s animal health biologics platform.
Dr. Guillemette brings more than 30 years of executive experience in animal health therapeutics, having held leadership roles at Elanco, Bayer, Henry Schein, Chewy, and Trupanion. He currently serves as an Operating Partner at Archimed and will chair the newly formed Strategy and Technology Committee while also serving on the Audit Committee.
Dr. DiMarco contributes four decades of scientific leadership across human and animal health biologics. He previously spent 21 years as Vice President of R&D and Global Manufacturing at IDEXX Laboratories and earlier held scientific roles at Abbott Laboratories. He will serve on the Compensation, Nominations, and Strategy and Technology Committees.
The newly formed Strategy and Technology Committee will support management in advancing innovation initiatives, improving manufacturing yields, expanding capacity, and driving growth of ImmuCell’s flagship First Defense product line. The governance update also reflects the company’s transition to a more independent board structure.
As part of these changes, several board members will retire, including Bryan Gathagan, Michael Brigham, and Bobbi Brockmann effective April 15, 2026, and Timothy Fiori following the 2026 Annual Meeting. Brockmann and Fiori will continue in their executive roles at the company.
ImmuCell, headquartered in Portland, Maine, develops and markets biologics that improve the health and productivity of dairy and beef calves. Its primary product line, First Defense, delivers colostrum-derived antibodies designed to protect against major causes of scours, a leading health risk in neonatal calves.
KEY QUOTES:
“My first introduction was in helping ImmuCell develop a manufacturing yield improvement plan and I look forward to working with the team to consider opportunities to further develop hyperimmune colostrum technology and expand the First Defense line.”
Dr. Anthony DiMarco, Board Member, ImmuCell Corporation
“This is an exciting time to join the ImmuCell Board as the company develops and executes new innovation strategies to accelerate the growth of First Defense.”
Dr. Gilles Guillemette, Board Member, ImmuCell Corporation
“Dr. Guillemette strengthens our board with expertise in animal health strategy and M&A, complemented by a veterinary background that will help us develop an innovation strategy based on clinical relevance. Dr. DiMarco brings experience improving biological manufacturing processes and a track record of developing successful new animal health products. Joined by Gloria Basse and Kathy Turner, they will serve on our new Strategy and Technology Committee that will support management with strategic and technical expertise as we pursue opportunities to improve our yield, expand our capacity, and generate innovation-driven growth of First Defense. We are also pleased to advance our corporate governance by moving to an independent board.”
Olivier te Boekhorst, President And Chief Executive Officer, ImmuCell Corporation
